Single Peptides class
It is an autoimmune disease with other comorbidity diseases and an increased risk of other conditions which should be properly monitored and managed even if we are a very long way from that being the reality in the UK
By Patricia Van Arnum, Editorial Director, DCAT, [email protected] Whats next Glucagon-like peptide 1 (GLP-1) agonists, used to treat Type 2 diabetes and obesity, have been a success story in the industry, with Novo Nordisk riding a blockbuster wave with Ozempic/Wegovy (semaglutide), respectively for treating Type 2 diabetes and obesity, and Eli Lilly and Company also riding the wave with Mounjaro/Zepbound (tirzepatide), a dual-activating GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 medication, respectively for treating Type 2 diabetes and obesity
On the other hand, Takeuchi et al
Think of it as your skin asking questions before accepting the new ingredient into its routine
The simplest solution is to use a 10 mg vial and reconstitute it all, since at escalating doses you will use it faster and the math stays clean